bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Fig. S1 from Vaccination with LAG-3Ig (IMP321) and Peptides Induces Specific CD4 and CD8 T-Cell Responses in Metastatic Melanoma Patients—Report of a Phase I/IIa Clinical Trial
Authors: Legat Amandine , Maby-El Hajjami Hélène , Baumgaertner Petra , Cagnon Laurène , Abed Maillard Samia , Geldhof Christine , Iancu Emanuela M. , Lebon Luc , Guillaume Philippe , Dojcinovic Danijel , Michielin Olivier , Romano Emanuela , Berthod Grégoire , Rimoldi Donata , Triebel Frédéric , Luescher Immanuel , Rufer Nathalie , Speiser Daniel E.
Published: April 2023

Gating strategy of combinatorial tetramer staining
Supplementary Tables 1-2 from DNA-PK—A Candidate Driver of Hepatocarcinogenesis and Tissue Biomarker That Predicts Response to Treatment and Survival
Authors: Cornell Liam , Munck Joanne M. , Alsinet Clara , Villanueva Augusto , Ogle Laura , Willoughby Catherine E. , Televantou Despina , Thomas Huw D. , Jackson Jennifer , Burt Alastair D. , Newell David , Rose John , Manas Derek M. , Shapiro Geoffrey I. , Curtin Nicola J. , Reeves Helen L.
Published: April 2023

Supplementary Tables 1-2. Supplementary Table 1. Clinical features of the subset of patients receiving palliative TACE as first line therapy Supplementary Table 2 - Tumour Factors associated with survival in cohort two
Supplementary Figure 3 from Loss of SMAD4 Promotes Colorectal Cancer Progression by Accumulation of Myeloid-Derived Suppressor Cells through the CCL15–CCR1 Chemokine Axis
Authors: Inamoto Susumu , Itatani Yoshiro , Yamamoto Takamasa , Minamiguchi Sachiko , Hirai Hideyo , Iwamoto Masayoshi , Hasegawa Suguru , Taketo Makoto Mark , Sakai Yoshiharu , Kawada Kenji
Published: April 2023

Double immunofluorescence staining with several cell markers in order to characterize CCR1+ cells.
Data Supplement from DNA-PK—A Candidate Driver of Hepatocarcinogenesis and Tissue Biomarker That Predicts Response to Treatment and Survival
Authors: Cornell Liam , Munck Joanne M. , Alsinet Clara , Villanueva Augusto , Ogle Laura , Willoughby Catherine E. , Televantou Despina , Thomas Huw D. , Jackson Jennifer , Burt Alastair D. , Newell David , Rose John , Manas Derek M. , Shapiro Geoffrey I. , Curtin Nicola J. , Reeves Helen L.
Published: April 2023

Data Supplement from DNA-PK—A Candidate Driver of Hepatocarcinogenesis and Tissue Biomarker That Predicts Response to Treatment and Survival
Supplementary Tables 1-5, Supplementary Methods and Materials from Targeting Notch Signaling with a Notch2/Notch3 Antagonist (Tarextumab) Inhibits Tumor Growth and Decreases Tumor-Initiating Cell Frequency
Authors: Yen Wan-Ching , Fischer Marcus M. , Axelrod Fumiko , Bond Christopher , Cain Jennifer , Cancilla Belinda , Henner William R. , Meisner Rene , Sato Aaron , Shah Jalpa , Tang Tracy , Wallace Breanna , Wang Min , Zhang Chun , Kapoun Ann M. , Lewicki John , Gurney Austin , Hoey Timothy
Published: April 2023

Table S1: OMP-59R5 binding data as assessed by surface plasmon resonance (Biacore); Table S2. Histopathology of human pancreatic tumors; Table S3. Effect of anti-Notch2/3 antibody OMP-59R5 in combination with gemcitabine on growth of pancreatic xenograft tumors and its association with Kras mutation status and molecular subtypes; Table S4. Gene Set Enrichment Analysis; Table S5. Effects of OMP-59R5 on Mouse Gene Expression in the Stroma of Xenograft Tumors.
Supplementary Table S3: In vivo potentiation of chemotherapeutic agents from Molecular Pathways: The eIF4F Translation Initiation Complex—New Opportunities for Cancer Treatment
Authors: Malka-Mahieu Hélène , Newman Michelle , Désaubry Laurent , Robert Caroline , Vagner Stéphan
Published: April 2023

Supplementary Table 3: In vivo potentiation of chemotherapeutic agents
Supplemental Tables S1-S4 and S6-S13 from Mutational Landscape of Aggressive Cutaneous Squamous Cell Carcinoma
Authors: Pickering Curtis R. , Zhou Jane H. , Lee J. Jack , Drummond Jennifer A. , Peng S. Andrew , Saade Rami E. , Tsai Kenneth Y. , Curry Jonathan L. , Tetzlaff Michael T. , Lai Stephen Y. , Yu Jun , Muzny Donna M. , Doddapaneni Harshavardhan , Shinbrot Eve , Covington Kyle R. , Zhang Jianhua , Seth Sahil , Caulin Carlos , Clayman Gary L. , El-Naggar Adel K. , Gibbs Richard A. , Weber Randal S. , Myers Jeffrey N. , Wheeler David A. , Frederick Mitchell J.
Published: April 2023

Supplemental Tables S1-S4 and S6-S13. Supplemental Table S1: Summary of Patient Characteristics. Supplemental Table S2: Patient Characteristics and Key Mutations. Supplemental Table S3: Tumor purity and ploidy calculations. Supplemental Table S4: Sequencing Coverages. Supplemental Table S6: Allele fraction analysis. Supplemental Table S7: MutSig analysis. Supplemental Table S8: IntOGen mutational significance analysis. Supplemental Table S9: Chi-square mutational significance analysis. Supplemental Table S10: Multinomial mutational significance analysis. Supplemental Table S11: Kappa analysis for gene-gene associations. Supplemental Table S12: ABSOLUTE copy number analysis segmentation data. Supplemental Table S13: Clinical and mutation associations.
Supplementary Table S2: Clinical consequences from Molecular Pathways: The eIF4F Translation Initiation Complex—New Opportunities for Cancer Treatment
Authors: Malka-Mahieu Hélène , Newman Michelle , Désaubry Laurent , Robert Caroline , Vagner Stéphan
Published: April 2023

Supplementary Table 2: Clinical consequences
Supplemental Figures and Methods from Mutational Landscape of Aggressive Cutaneous Squamous Cell Carcinoma
Authors: Pickering Curtis R. , Zhou Jane H. , Lee J. Jack , Drummond Jennifer A. , Peng S. Andrew , Saade Rami E. , Tsai Kenneth Y. , Curry Jonathan L. , Tetzlaff Michael T. , Lai Stephen Y. , Yu Jun , Muzny Donna M. , Doddapaneni Harshavardhan , Shinbrot Eve , Covington Kyle R. , Zhang Jianhua , Seth Sahil , Caulin Carlos , Clayman Gary L. , El-Naggar Adel K. , Gibbs Richard A. , Weber Randal S. , Myers Jeffrey N. , Wheeler David A. , Frederick Mitchell J.
Published: April 2023

Supplemental Figures S1-S2 and Methods. Figure S1: Mutation types and number by previous radiation treatment. Figure S2: Copy number alterations.
Supplementary Figure S6 from Integrating RAS Status into Prognostic Signatures for Adenocarcinomas of the Lung
Authors: Starmans Maud HW. , Pintilie Melania , Chan-Seng-Yue Michelle , Moon Nathalie C. , Haider Syed , Nguyen Francis , Lau Suzanne K. , Liu Ni , Kasprzyk Arek , Wouters Bradly G. , Der Sandy D. , Shepherd Frances A. , Jurisica Igor , Penn Linda Z. , Tsao Ming-Sound , Lambin Philippe , Boutros Paul C.
Published: April 2023

Supplementary Figure S6. Prognostic signatures derived from all NSCLC patients consistently perform better in RASwt than in RASmt patients in current studies where the number of RASmt patients is smaller compared to the number of RASwt patients (A-C). When balancing the number of RASwt and RASmt patients it is clear that different signatures are prognostic in these patient groups (D-F). A,D, Distribution of logged HR in all, only RASwt and only RASmt patients (combined permutations of 5 - 100 genes). B,E, Percentages of random signatures vs. logged p-values in all, only RASwt and only RASmt patients (combined permutations of 5 - 100 genes). C,F, Log-odds of p-value Wald test in RASmt vs. p-value in RASwt patient groups as a function of gene-set size.
Supplementary Methods, Figures S1-S8, Tables S1-S7 from Effective Targeting of the P53–MDM2 Axis in Preclinical Models of Infant MLL-Rearranged Acute Lymphoblastic Leukemia
Authors: Richmond Jennifer , Carol Hernan , Evans Kathryn , High Laura , Mendomo Agnes , Robbins Alissa , Meyer Claus , Venn Nicola C. , Marschalek Rolf , Henderson Michelle , Sutton Rosemary , Kurmasheva Raushan T. , Kees Ursula R. , Houghton Peter J. , Smith Malcolm A. , Lock Richard B.
Published: April 2023

This file contains Supplementary Methods describing the Pediatric Preclinical Testing Program (PPTP) scoring method. Supplementary Figure S1: Engraftment rates and organ infiltration of MLL-ALL xenografts. Supplementary Figure S2: Comparison of expression of specific genes between MLL-ALL and BCP-ALL xenografts. Supplementary Figure S3: Comparison of HOXA gene expression between MLL-ALL and BCP-ALL xenografts. Supplementary Figure S4: RG7112 induces caspase-dependent cell death in RS4;11 cells. Supplementary Figure S5: In vivo efficacy of RG7112 against MLL-ALL xenografts. Supplementary Figure S6: Effects of RG7112 on mouse weight and haematological parameters. Supplementary Figure S7: Immunoblots of spleen-derived cells from replicate mice showing the effects of RG7112 on MLL-14 xenograft cells. Supplementary Figure S8: Relationships between TP53 and MDM2 gene expression and in vivo responses of ALL xenografts to RG7112. Supplementary Table S1: Rates of serial engraftment of MLL-ALL xenografts. Supplementary Table S2: The top 100 genes that distinguish MLL-rearranged ALL xenografts from BCP-ALL xenografts. Supplementary Table S3: Statistical analysis of genes identified by Armstrong et al (2002) between MLL-ALL and BCP-ALL xenografts. Supplementary Table S4: Details of individual mouse responses to in vivo treatment with RG7112. Supplementary Table S5: In vitro Combination Indices of RG7112 with established drugs used to treat ALL. Supplementary Table S6: In vivo efficacy of RG7112 in combination with a VXL induction-type regimen. Supplementary Table S7: Details of individual mouse responses to in vivo treatment with RG7112 combined with VXL against MLL-ALL xenografts.
Supplementary Figure Legends & Tables from Integrating RAS Status into Prognostic Signatures for Adenocarcinomas of the Lung
Authors: Starmans Maud HW. , Pintilie Melania , Chan-Seng-Yue Michelle , Moon Nathalie C. , Haider Syed , Nguyen Francis , Lau Suzanne K. , Liu Ni , Kasprzyk Arek , Wouters Bradly G. , Der Sandy D. , Shepherd Frances A. , Jurisica Igor , Penn Linda Z. , Tsao Ming-Sound , Lambin Philippe , Boutros Paul C.
Published: April 2023

Supplementary Figure Legends and Supplementary Tables. Supplementary Table S1: Link to patient microarray datasets. Supplementary Table S2: genes in the RAS pathway activation status predictor. Supplementary Table S3: Prediction accuracy of the RAS status predictor and the previously published RAS pathway dependency signature (Loboda signature). Supplementary Table S4: Results for univariate Cox proportional hazard modeling of the 3-gene and 6-gene signatures in the datasets without RAS mutation status split by RAS pathway activation status with the 14-gene RAS predictor.
Supplemental Figure A Legend from Quantification of Nonenhancing Tumor Burden in Gliomas Using Effective T2 Maps Derived from Dual-Echo Turbo Spin-Echo MRI
Authors: Ellingson Benjamin M. , Lai Albert , Nguyen Huytram N. , Nghiemphu Phioanh L. , Pope Whitney B. , Cloughesy Timothy F.
Published: April 2023

Supplemental Figure A Legend. File containing the figure legend for Supplemental Figure A.
Panel of flow cytometry antibodies from Vaccination with Irradiated Autologous Tumor Cells Mixed with Irradiated GM-K562 Cells Stimulates Antitumor Immunity and T Lymphocyte Activation in Patients with Recurrent Malignant Glioma
Authors: Curry William T. , Gorrepati Ramana , Piesche Matthias , Sasada Tetsuro , Agarwalla Pankaj , Jones Pamela S. , Gerstner Elizabeth R. , Golby Alexandra J. , Batchelor Tracy T. , Wen Patrick Y. , Mihm Martin C. , Dranoff Glenn
Published: April 2023

Full flow cytometry panel for white blood cell immunophenotyping.
Lymphocyte Immunophenotyping methods from Vaccination with Irradiated Autologous Tumor Cells Mixed with Irradiated GM-K562 Cells Stimulates Antitumor Immunity and T Lymphocyte Activation in Patients with Recurrent Malignant Glioma
Authors: Curry William T. , Gorrepati Ramana , Piesche Matthias , Sasada Tetsuro , Agarwalla Pankaj , Jones Pamela S. , Gerstner Elizabeth R. , Golby Alexandra J. , Batchelor Tracy T. , Wen Patrick Y. , Mihm Martin C. , Dranoff Glenn
Published: April 2023

Extended methods for flow cytometry for lymphocyte phenotyping.
Supplementary Fig. S4 from Model Matters: Differences in Orthotopic Rat Hepatocellular Carcinoma Physiology Determine Therapy Response to Sorafenib
Authors: Groß Claudia , Steiger Katja , Sayyed Sufyan , Heid Irina , Feuchtinger Annette , Walch Axel , Heß Julia , Unger Kristian , Zitzelsberger Horst , Settles Marcus , Schlitter Anna Melissa , Dworniczak Juliane , Altomonte Jennifer , Ebert Oliver , Schwaiger Markus , Rummeny Ernst , Steingötter Andreas , Esposito Irene , Braren Rickmer
Published: April 2023

Supplementary Fig. S4. Tumor vascularization and necrosis in human HCC.
Histopathological scoring system from Vaccination with Irradiated Autologous Tumor Cells Mixed with Irradiated GM-K562 Cells Stimulates Antitumor Immunity and T Lymphocyte Activation in Patients with Recurrent Malignant Glioma
Authors: Curry William T. , Gorrepati Ramana , Piesche Matthias , Sasada Tetsuro , Agarwalla Pankaj , Jones Pamela S. , Gerstner Elizabeth R. , Golby Alexandra J. , Batchelor Tracy T. , Wen Patrick Y. , Mihm Martin C. , Dranoff Glenn
Published: April 2023

Detailed description of histopathological scoring of vaccination site and delayed-type hypersensitivity biopsies.
Supplementary Fig. S2 from Model Matters: Differences in Orthotopic Rat Hepatocellular Carcinoma Physiology Determine Therapy Response to Sorafenib
Authors: Groß Claudia , Steiger Katja , Sayyed Sufyan , Heid Irina , Feuchtinger Annette , Walch Axel , Heß Julia , Unger Kristian , Zitzelsberger Horst , Settles Marcus , Schlitter Anna Melissa , Dworniczak Juliane , Altomonte Jennifer , Ebert Oliver , Schwaiger Markus , Rummeny Ernst , Steingötter Andreas , Esposito Irene , Braren Rickmer
Published: April 2023

Supplementary Fig. S2. Macrophage and T-lymphocyte infiltration in DEN and McA animals.
Supplementary table 3 from Neoadjuvant Chemotherapy Modulates the Immune Microenvironment in Metastases of Tubo-Ovarian High-Grade Serous Carcinoma
Authors: Böhm Steffen , Montfort Anne , Pearce Oliver M.T. , Topping Joanne , Chakravarty Probir , Everitt Gemma L.A. , Clear Andrew , McDermott Jackie R. , Ennis Darren , Dowe Thomas , Fitzpatrick Amanda , Brockbank Elly C. , Lawrence Alexandra C. , Jeyarajah Arjun , Faruqi Asma Z. , McNeish Iain A. , Singh Naveena , Lockley Michelle , Balkwill Frances R.
Published: April 2023

Cohort per experiment
Supplemental Figures from Fluorescent Image–Guided Surgery with an Anti-Prostate Stem Cell Antigen (PSCA) Diabody Enables Targeted Resection of Mouse Prostate Cancer Xenografts in Real Time
Authors: Sonn Geoffrey A. , Behesnilian Andrew S. , Jiang Ziyue Karen , Zettlitz Kirstin A. , Lepin Eric J. , Bentolila Laurent A. , Knowles Scott M. , Lawrence Daniel , Wu Anna M. , Reiter Robert E.
Published: April 2023

Figure S1. Biochemical characterization of Cy5 conjugated anti-PSCA cys-Diabody. Figure S2. Validation of in vivo tumor detection using endogenously PSCA-expressing line LAPC-9 Figure S3. Determining the optimal time point for in vivo Cy5-cDb imaging. Figure S4. Cy5-cDb enabled fluorescence-guided surgical resection of PSCA-expressing tumors. Figure S5. LAPC-9 intramuscular tumor extent was not readily detectable under white light (A-B), but was clearly visible under fluorescence guidance (C). Figure S6. Intraoperative white light and florescent images of 22Rv1 intramuscular xenografts utilizing anti-PSCA Cy5-cDb. Figure S7. Additional H&E histopathology of tumor margins from the prospective, randomized trial.
Supplementary Materials and Methods from The Impact of Macrophage- and Microglia-Secreted TNFα on Oncolytic HSV-1 Therapy in the Glioblastoma Tumor Microenvironment
Authors: Meisen W. Hans , Wohleb Eric S. , Jaime-Ramirez Alena Cristina , Bolyard Chelsea , Yoo Ji Young , Russell Luke , Hardcastle Jayson , Dubin Samuel , Muili Kamaldeen , Yu Jianhua , Caligiuri Michael , Godbout Jonathan , Kaur Balveen
Published: April 2023

Supplementary Materials and Methods
Supplementary Figure Legend from A Phase I Clinical Trial and Independent Patient-Derived Xenograft Study of Combined Targeted Treatment with Dacomitinib and Figitumumab in Advanced Solid Tumors
Authors: Calvo Emiliano , Soria Jean-Charles , Ma Wen Wee , Wang Tao , Bahleda Rastilav , Tolcher Anthony W. , Gernhardt Diana , O'Connell Joseph , Millham Robert , Giri Nagdeep , Wick Michael J. , Adjei Alex A. , Hidalgo Manuel
Published: April 2023

Supplementary Figure Legend
CLEAN supplementary material Daco+figi 1004 CCR Sesub v4.0 from A Phase I Clinical Trial and Independent Patient-Derived Xenograft Study of Combined Targeted Treatment with Dacomitinib and Figitumumab in Advanced Solid Tumors
Authors: Calvo Emiliano , Soria Jean-Charles , Ma Wen Wee , Wang Tao , Bahleda Rastilav , Tolcher Anthony W. , Gernhardt Diana , O'Connell Joseph , Millham Robert , Giri Nagdeep , Wick Michael J. , Adjei Alex A. , Hidalgo Manuel
Published: April 2023

Supplementary material Supplementary Table 1. Customized primer panel for Sequenom MassARRAYÂ® somatic mutation profiling of DNA from models of adenoid cystic carcinoma. Supplementary Figure 1. Apparent oral clearance (CL/F) of dacomitinib 10 mg (D-1b) and 15 mg (D-1d) in the presence of figitumumab (20 mg/kg). Boxes, 25th-75th percentiles (1st-3rd quartiles); circles individual patient values; horizontal black bars, medians; whiskers, 1.5 Ã- interquartile range. Supplementary Figure 2. Dose-normalized maximal plasma concentration (Cmax; A) and area under the concentration-time curve (AUC24; B) for dacomitinib 10 mg (D-1b) and 15 mg (D-1d) in the presence of figitumumab (20 mg/kg) (Pfizer, data on file). Boxes, 25th-75th percentiles (1st-3rd quartiles); circles individual patient values; horizontal black bars, medians; whiskers, 1.5 Ã- interquartile range. Supplementary Figure 3. Apparent oral clearance (CL/F) of dacomitinib in the presence (cohorts D-1b and D-1d in this study [study 1004]) and the absence (studies 1001, 1003, and 1005) of figitumumab (20 mg/kg) (Pfizer, data on file). Boxes, 25th-75th percentiles (1st-3rd quartiles); circles individual patient values; horizontal black bars, medians; whiskers, 1.5 Ã- interquartile range. Supplementary Figure 4. Dose-normalized maximal plasma concentration (Cmax; A) and area under the concentration-time curve (AUC24; B) for dacomitinib in the presence (cohorts D-1b and D-1d in this study [study 1004]) and the absence (studies 1001, 1003, and 1005) of figitumumab (20 mg/kg) (Pfizer, data on file). Boxes, 25th-75th percentiles (1st-3rd quartiles); circles individual patient values; horizontal black bars, medians; whiskers, 1.5 Ã- interquartile range.
Supplemental Figure S1 from The Impact of Macrophage- and Microglia-Secreted TNFα on Oncolytic HSV-1 Therapy in the Glioblastoma Tumor Microenvironment
Authors: Meisen W. Hans , Wohleb Eric S. , Jaime-Ramirez Alena Cristina , Bolyard Chelsea , Yoo Ji Young , Russell Luke , Hardcastle Jayson , Dubin Samuel , Muili Kamaldeen , Yu Jianhua , Caligiuri Michael , Godbout Jonathan , Kaur Balveen
Published: April 2023

Supplemental Figure S1. Percoll gradient isolated CD11b+CD45hi cells are predominantly infiltrating macrophages
Supplementary Figure S5 from Integrative Analysis of Head and Neck Cancer Identifies Two Biologically Distinct HPV and Three Non-HPV Subtypes
Authors: Keck Michaela K. , Zuo Zhixiang , Khattri Arun , Stricker Thomas P. , Brown Christopher D. , Imanguli Matin , Rieke Damian , Endhardt Katharina , Fang Petra , Brägelmann Johannes , DeBoer Rebecca , El-Dinali Mohamed , Aktolga Serdal , Lei Zhengdeng , Tan Patrick , Rozen Steve G. , Salgia Ravi , Weichselbaum Ralph R. , Lingen Mark W. , Story Michael D. , Ang K. Kian , Cohen Ezra E.W. , White Kevin P. , Vokes Everett E. , Seiwert Tanguy Y.
Published: April 2023

Supplementary Figure S5. Immunohistochemistry shows the difference among subtypes (A) Protein levels as determined by immunohistochemistry (IHC) (N=47) for the differentiation of the three super-groups and five subtypes (B) Representative examples of IHC staining of HNC samples for key genes, such as SOX2, CDKN2A, CCDN1 and TP63.
Supplementary Figure S3 from Integrative Analysis of Head and Neck Cancer Identifies Two Biologically Distinct HPV and Three Non-HPV Subtypes
Authors: Keck Michaela K. , Zuo Zhixiang , Khattri Arun , Stricker Thomas P. , Brown Christopher D. , Imanguli Matin , Rieke Damian , Endhardt Katharina , Fang Petra , Brägelmann Johannes , DeBoer Rebecca , El-Dinali Mohamed , Aktolga Serdal , Lei Zhengdeng , Tan Patrick , Rozen Steve G. , Salgia Ravi , Weichselbaum Ralph R. , Lingen Mark W. , Story Michael D. , Ang K. Kian , Cohen Ezra E.W. , White Kevin P. , Vokes Everett E. , Seiwert Tanguy Y.
Published: April 2023

Supplementary Figure S3. Pathway annotation for HNSCC super-groups. Each horizontal bar graph represents enriched pathways in different subtypes. The number at the end of bar is the total number of genes in a pathway. Percentage of genes in the dataset that overlap with the pathway are shown in grey colour of the bar. The trend line represents the -log(p-value).
Supplementary Figure S4 from Dysregulation of miR-212 Promotes Castration Resistance through hnRNPH1-Mediated Regulation of AR and AR-V7: Implications for Racial Disparity of Prostate Cancer
Authors: Yang Yijun , Jia Dingwu , Kim Hogyoung , Abd Elmageed Zakaria Y. , Datta Amrita , Davis Rodney , Srivastav Sudesh , Moroz Krzysztof , Crawford Byron E. , Moparty Krishnarao , Thomas Raju , Hudson Robert S. , Ambs Stefan , Abdel-Mageed Asim B.
Published: April 2023

qRT-PCR analysis of miR-132 and miR-495 expression in microdissected prostate tumors
Supplementary Figures 1-13 from PEST Domain Mutations in Notch Receptors Comprise an Oncogenic Driver Segment in Triple-Negative Breast Cancer Sensitive to a γ-Secretase Inhibitor
Authors: Wang Kai , Zhang Qin , Li Danan , Ching Keith , Zhang Cathy , Zheng Xianxian , Ozeck Mark , Shi Stephanie , Li Xiaorong , Wang Hui , Rejto Paul , Christensen James , Olson Peter
Published: April 2023

Supplementary Figures 1-13 Supplementary Figure 1: Simple mutations and copy number alterations in NOTCH1, NOTCH2 and NOTCH3. Supplementary Figure 2: Simple mutations and copy number alterations in NOTCH4. Supplementary Figure 3: Complex alterations identified by TopNotch Supplementary Figure 4: Intra-NOTCH1 deletion in TCGA-BH-A1FC. Supplementary Figure 5: BRD4-NOTCH3 fusion and PEST domain deletion in TCGA-AN-A0AR. Supplementary Figure 6: Three PEST domain alterations identified in the TCGA breast cancer dataset. Supplementary Figure 7: Notch altered tumors often exhibit increased pathway activity. Supplementary Figure 8: Notch aberrations in pre-clinical GSI sensitive models. Supplementary Figure 9: NOTCH1 aberrations in the HBCx-14 breast cancer PDX model. Supplementary Figure 10: Tumor growth inhibition plots of PF-03084014 in Notch wt models Supplementary Figure 11: Comparison of NICD1 between Notch wt and mutant models. Supplementary Figure 12: Quantitative RT-PCR of HES and HEY target genes in Notch wt and mutant xenograft models Supplementary Figure 13:Quantitative RT-PCR of Notch target genes in Notch wt and mutant xenograft models
Supplementary Tables 1-5, Figures 1-2 from Head-to-Head Comparison and Evaluation of 92 Plasma Protein Biomarkers for Early Detection of Colorectal Cancer in a True Screening Setting
Authors: Chen Hongda , Zucknick Manuela , Werner Simone , Knebel Phillip , Brenner Hermann
Published: April 2023

Supporting Information: Table S1. Abbreviations and full names of the 92 protein biomarkers studied. Table S2. Head-to-head comparison of the diagnostic performance for 92 protein biomarkers Table S3. Eight-marker algorithm derived through the Lasso Logistic regression model. Table S4. Characteristics of study population in the independent validation set. Table S5. Comparison of significant biomarkers between current study and the study by Thorsen. Figure S1. The percentage of limit of detection (LOD) and missing data for each of 92 protein biomarkers in all the tested plasma samples. Figure S2. Box plots of plasma levels for 17 protein biomarkers: (a) between CRC cases and controls; (b) early stages (I/II) and advanced stage (III/IV) CRC. The bottom and top of the box indicate the first (Q1) and third (Q3) quartiles, and the middle line in the box is the median; the upper-limit equals Q3 plus 1.5 times interquartile range (IQR), and the lower-limit equals Q1 minus 1.5 times IQR.
supplementary table 2 from PIK3CA Pathway Mutations Predictive of Poor Response Following Standard Radiochemotherapy ± Cetuximab in Cervical Cancer Patients
Authors: de la Rochefordiere Anne , Kamal Maud , Floquet Anne , Thomas Laurence , Petrow Peter , Petit Thierry , Pop Marius , Fabbro Michel , Kerr Christine , Joly Florence , Sevin Emmanuel , Maillard Sophie , Curé Hervé , Weber Béatrice , Brunaud Claire , Minsat Mathieu , Gonzague Laurence , Berton-Rigaud Dominique , Aumont Maud , Gladieff Laurence , Peignaux Karine , Bernard Virginie , Leroy Quentin , Bieche Ivan , Margogne Audrey , Nadan AnaTereza , Fourchotte Virginie , Diallo Alhassane , Asselain Benard , Plancher Corine , Armanet Sébastien , Beuzeboc Philippe , Scholl Suzy M.
Published: April 2023

supplementary table 2. Protocolâ€�defined treatmentâ€�related Adverse Events
Supplementary Figure S4 from HDAC Inhibition Overcomes Acute Resistance to MEK Inhibition in BRAF-Mutant Colorectal Cancer by Downregulation of c-FLIPL
Authors: Carson Robbie , Celtikci Basak , Fenning Cathy , Javadi Arman , Crawford Nyree , Perez-Carbonell Lucia , Lawler Mark , Longley Daniel B. , Johnston Patrick G. , Van Schaeybroeck Sandra
Published: April 2023

Supplementary Figure S4. BRAFMT CRC cells respond to MEKi with increases in c-FLIPL expression levels.
supplementary methods from Circulating DNA as a Strong Multimarker Prognostic Tool for Metastatic Colorectal Cancer Patient Management Care
Authors: El Messaoudi Safia , Mouliere Florent , Du Manoir Stanislas , Bascoul-Mollevi Caroline , Gillet Brigitte , Nouaille Michelle , Fiess Catherine , Crapez Evelyne , Bibeau Frederic , Theillet Charles , Mazard Thibault , Pezet Denis , Mathonnet Muriel , Ychou Marc , Thierry Alain R.
Published: April 2023

rationale for sample size of the studied cohort
Supplementary Figure S3 from HDAC Inhibition Overcomes Acute Resistance to MEK Inhibition in BRAF-Mutant Colorectal Cancer by Downregulation of c-FLIPL
Authors: Carson Robbie , Celtikci Basak , Fenning Cathy , Javadi Arman , Crawford Nyree , Perez-Carbonell Lucia , Lawler Mark , Longley Daniel B. , Johnston Patrick G. , Van Schaeybroeck Sandra
Published: April 2023

Supplementary Figure S3. Identification of the upstream receptor tyrosine kinase cMET regulating STAT3 activity in the context of MEK1/2 inhibition in BRAFMT CRC cells.
Supplementary Figures 1 - 9 from Genomic Alterations in the RB Pathway Indicate Prognostic Outcomes of Early-Stage Lung Adenocarcinoma
Authors: Choi Seongmin , Kim Hyeong Ryul , Sung Chang Ohk , Kim Jongkyu , Kim Sukjun , Ahn Sung-Min , Choi Chang-min , Chun Sung-Min , Choi Eun Kyung , Kim Sang-We , Kim Yong-Hee , Lee Ji-Young , Song Joon Seon , Kim Deokhoon , Haq Farhan , Lee Sun Young , Lee Jong-eun , Jung Wang-rim , Jang Hye Yoon , Yang Eunho , Lee Charles , Yu Eunsil , Kong Gu , Baek Daehyun , Jang Se Jin
Published: April 2023

Supplementary Figures 1 - 9. Supp. Figure 1. Comparison of mutation rates between never-smokers and smokers. Supp. Figure 2. Druggable gene candidates. Supp. Figure 3. Prevalence of somatic mutations and the CNVs of the genes in the RB pathway. Supp. Figure 4. Association between RB pathway alterations and poor prognosis in early-stage LA patients who were not treated with adjuvant chemotherapy. Supp. Figure 5. Disease-free survival curve of randomly resampled early-stage LA patients included in the discovery cohort. Supp. Figure 6. Global landscape of significantly mutated genes and significantly altered CNV regions. Supp. Figure 7. Comparison of read depths for EGFR, KRAS, and BRAF. Supp. Figure 8. Mapped read depths of exome-captured regions of KEAP1 and STK11. Supp. Figure 9. Mutation rates between smokers and never-smokers.
Supplementary Figure S3 from A Phase I Trial of BKM120 (Buparlisib) in Combination with Fulvestrant in Postmenopausal Women with Estrogen Receptor–Positive Metastatic Breast Cancer
Authors: Ma Cynthia X. , Luo Jingqin , Naughton Michael , Ademuyiwa Foluso , Suresh Rama , Griffith Malachi , Griffith Obi L. , Skidmore Zachary L. , Spies Nicholas C. , Ramu Avinash , Trani Lee , Pluard Timothy , Nagaraj Gayathri , Thomas Shana , Guo Zhanfang , Hoog Jeremy , Han Jing , Mardis Elaine , Lockhart Craig , Ellis Matthew J.
Published: April 2023

Supplementary Fig. S3 Immunohistochemistry (IHC) for PTEN expression on archival tumor specimens
Stereotactic radiation with SARRP delivery system from Combination Therapy with Anti-PD-1, Anti-TIM-3, and Focal Radiation Results in Regression of Murine Gliomas
Authors: Kim Jennifer E. , Patel Mira A. , Mangraviti Antonella , Kim Eileen S. , Theodros Debebe , Velarde Esteban , Liu Ann , Sankey Eric W. , Tam Ada , Xu Haiying , Mathios Dimitrios , Jackson Christopher M. , Harris-Bookman Sarah , Garzon-Muvdi Tomas , Sheu Mary , Martin Allison M. , Tyler Betty M. , Tran Phuoc T. , Ye Xiaobu , Olivi Alessandro , Taube Janis M. , Burger Peter C. , Drake Charles G. , Brem Henry , Pardoll Drew M. , Lim Michael
Published: April 2023

Each mouse was individually imaged with cone beam computed tomography (CBCT) using the SARRP with a 65 kVp and 0.7 mA beam. Using the treatment planning system from the SARRP system (Muriplan) and the CBCT, the target was exactly placed 3mm below the skull's burr hole. The planning system calculated the x-ray beam's (220kVp and 13mA) time of exposure according to the prescribed dose and moved the motorized couch to its target location, after which a 3-mm beam centered on the burr hole and underlying tumor was used to administer a total of 10 Gy radiation per animal at a rate of 1.9 Gy/min (18). The isodose distribution is shown on the figure provided. The dose to adjacent organs or rest of the brain is insignificant as the beam's penumbra demonstrates complete drop off on the edge of the field (17, 50, 51)
Gating strategy for APC characterization from Combination Therapy with Anti-PD-1, Anti-TIM-3, and Focal Radiation Results in Regression of Murine Gliomas
Authors: Kim Jennifer E. , Patel Mira A. , Mangraviti Antonella , Kim Eileen S. , Theodros Debebe , Velarde Esteban , Liu Ann , Sankey Eric W. , Tam Ada , Xu Haiying , Mathios Dimitrios , Jackson Christopher M. , Harris-Bookman Sarah , Garzon-Muvdi Tomas , Sheu Mary , Martin Allison M. , Tyler Betty M. , Tran Phuoc T. , Ye Xiaobu , Olivi Alessandro , Taube Janis M. , Burger Peter C. , Drake Charles G. , Brem Henry , Pardoll Drew M. , Lim Michael
Published: April 2023

Cells were first gated on size and singularity by forward scatter and side scatter. Nonviable cells were excluded by live/dead gating. Live cells were gated on CD11c and CD11b, then on CD45 and F4/80 to identify macrophage and dendritic cell phenotypes. Finally myeloid cells were gated for expression of TIM-3. Final populations were (A) F4/80+CD45hiCD11c-CD11bhi (B) F4/80+CD45dimCD11bhi (C) F4/80+CD45hiCD11c+CD11b+ and (D) F4/80-CD45dimCD11c+CD11b-.
Supplementary Tables S1-S8 and Figures S1-S3 from DNA Topoisomerase I Gene Copy Number and mRNA Expression Assessed as Predictive Biomarkers for Adjuvant Irinotecan in Stage II/III Colon Cancer
Authors: Nygård Sune Boris , Vainer Ben , Nielsen Signe Lykke , Bosman Fred , Tejpar Sabine , Roth Arnaud , Delorenzi Mauro , Brünner Nils , Budinska Eva
Published: April 2023

Supplementary Table S1: Baseline characteristics of biomarker stage III vs PETACC3 stage III. Supplementary Table S2: Baseline characteristics of biomarker stage II + III vs PETACC3 stage II + III. Supplementary Table S3: Treatment effects in the biomarker populations vs PETACC3. Supplementary Table S4: Associations between the TOP1 gene copy number and baseline characteristics, stage II + III. Supplementary Table S5: Associations between the TOP1 gene copy number and baseline characteristics, stage III. Supplementary Table S6: Associations between the TOP1/CEN20 ratio and baseline characteristics, stage II + III. Supplementary Table S7: Associations between the TOP1/CEN20 ratio and baseline characteristics, stage III. Supplementary Table S8: Associations between TOP1 mRNA expression and baseline characteristics, stage III. Supplementary Figure S1: CONSORT diagram Supplementary Figure S2: Inter-observer agreement of FISH counting, Bland-Altman plots. Supplementary Figure S3: Correlation between TOP1 FISH and TOP1 mRNA expression.
Supplementary Figure S1 from CD47 Enhances In Vivo Functionality of Artificial Antigen-Presenting Cells
Authors: Bruns Heiko , Bessell Catherine , Varela Juan Carlos , Haupt Carl , Fang Jerry , Pasemann Shirin , Mackensen Andreas , Oelke Mathias , Schneck Jonathan P. , Schütz Christian
Published: April 2023

Supplementary Figure S1. HLA-A2-Ig and anti-CD28 expression of different aAPCCD47+
Supplementary Materials and Methods from UM-164: A Potent c-Src/p38 Kinase Inhibitor with In Vivo Activity against Triple-Negative Breast Cancer
Authors: Gilani Rabia A. , Phadke Sameer , Bao Li Wei , Lachacz Eric J. , Dziubinski Michele L. , Brandvold Kristoffer R. , Steffey Michael E. , Kwarcinski Frank E. , Graveel Carrie R. , Kidwell Kelley M. , Merajver Sofia D. , Soellner Matthew B.
Published: April 2023

Detailed experimental information for: Cell cycle analysis; Dose response studies; Western blot analyses; 3D cell culture; Bead motility assay; Cell invasion assays; General synthetic methods; Synthesis of UM-164.
Supplementary Figure Legends from UM-164: A Potent c-Src/p38 Kinase Inhibitor with In Vivo Activity against Triple-Negative Breast Cancer
Authors: Gilani Rabia A. , Phadke Sameer , Bao Li Wei , Lachacz Eric J. , Dziubinski Michele L. , Brandvold Kristoffer R. , Steffey Michael E. , Kwarcinski Frank E. , Graveel Carrie R. , Kidwell Kelley M. , Merajver Sofia D. , Soellner Matthew B.
Published: April 2023

Legends associated with Supplementary Figures S1-S12.
Supplementary Figure S3 from A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1-Rearranged Lung Cancer
Authors: Drilon Alexander , Somwar Romel , Wagner Jacob P. , Vellore Nadeem A. , Eide Christopher A. , Zabriskie Matthew S. , Arcila Maria E. , Hechtman Jaclyn F. , Wang Lu , Smith Roger S. , Kris Mark G. , Riely Gregory J. , Druker Brian J. , O'Hare Thomas , Ladanyi Marc , Davare Monika A.
Published: April 2023

Sensitivity of CD74-ROS1D2033N to a spectrum of ROS1 kinase inhibitors. Cell growth and viability of Ba/F3 cells expressing native CD74-ROS1 or CD74-ROS1D2033N after 72 h exposure to (A) foretinib, (B) PF-06463922, (C) ceritinib, and (D) brigatinib. Results are shown as mean viability normalized to vehicle-treated control {plus minus} SEM (n = 3 to 6). (E) Table listing inhibitor IC50 (nM) for native versus ROS1D2033N mutant. (F) Graph depicts fold increase in IC50 (nM) for Ba/F3 cells expressing CD74-ROS1D2033N compared to native CD74-ROS1.
Supplementary Table 1 from Phase I, Dose-Escalation Study of the Targeted Cytotoxic LHRH Analog AEZS-108 in Patients with Castration- and Taxane-Resistant Prostate Cancer
Authors: Liu Stephen V. , Tsao-Wei Denice D. , Xiong Shigang , Groshen Susan , Dorff Tanya B. , Quinn David I. , Tai Yu-Chong , Engel Juergen , Hawes Debra , Schally Andrew V. , Pinski Jacek K.
Published: April 2023

Supplemental Table 1. Baseline disease characteristics describing site of disease as bone, lymph node, and/or visceral involvement, with organ noted.
Supplementary Figure 5 from c-Myc Modulation and Acetylation Is a Key HDAC Inhibitor Target in Cancer
Authors: Nebbioso Angela , Carafa Vincenzo , Conte Mariarosaria , Tambaro Francesco Paolo , Abbondanza Ciro , Martens Joost , Nees Matthias , Benedetti Rosaria , Pallavicini Isabella , Minucci Saverio , Garcia-Manero Guillermo , Iovino Francesco , Lania Gabriella , Ingenito Concetta , Belsito Petrizzi Valeria , Stunnenberg Hendrik G. , Altucci Lucia
Published: April 2023

HDACi effects in different cell lines.
Supplementary Figure 1 from Hedgehog Pathway Inhibitors Promote Adaptive Immune Responses in Basal Cell Carcinoma
Authors: Otsuka Atsushi , Dreier Jil , Cheng Phil F. , Nägeli Mirjam , Lehmann Holger , Felderer Lea , Frew Ian J. , Matsushita Shigeto , Levesque Mitchell P. , Dummer Reinhard
Published: April 2023

Figure S1: Negative control for immunofluorescence and immunohistochemistry (A) Negative control for Cilia, and Sox9 (B) Representative image of negative control for CD4, CD8, FoxP3, MHC class I and HLA-DR-class II staining using tonsil.
AVPC Molecular Signature Supplementary Figures from Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate Cancers
Authors: Aparicio Ana M. , Shen Li , Tapia Elsa Li Ning , Lu Jing-Fang , Chen Hsiang-Chun , Zhang Jiexin , Wu Guanglin , Wang Xuemei , Troncoso Patricia , Corn Paul , Thompson Timothy C. , Broom Bradley , Baggerly Keith , Maity Sankar N. , Logothetis Christopher J.
Published: April 2023

Supplementary Figure 1. Supervised hierarchical clustering of differentially expressed genes between typical CRPC PDX ("ADENO") and CRPC PDX with small cell carcinoma morphology ("SCPC"). Supplementary Figure 2. Morphologic spectrum of tumors of patients with the aggressive variant phenotype in the primary (A-D) and metastatic tumor sites (E-H) Supplementary Figure 3. Immunohistochemical analysis of all 59 available NCT00514540 samples and 8 PDX lines. Supplementary Figure 4. Principal component analysis of a16-serum-and-IHC-tumor-marker set in "Baseline" samples from 21 patients. Supplementary Figure 5. Total number of copy number alterations per sample. Supplementary Figure 6. mRNA levels of genes of interest. Supplementary Figure 7. Principal component analysis of a 10-CNA-marker set in TCGA, unsupervised CRPC and AVPC samples.
AVPC Molecular Signature Aparicio Supplementary Material from Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate Cancers
Authors: Aparicio Ana M. , Shen Li , Tapia Elsa Li Ning , Lu Jing-Fang , Chen Hsiang-Chun , Zhang Jiexin , Wu Guanglin , Wang Xuemei , Troncoso Patricia , Corn Paul , Thompson Timothy C. , Broom Bradley , Baggerly Keith , Maity Sankar N. , Logothetis Christopher J.
Published: April 2023

IHC, qRT-PCR and Western blot methods.
Supplemental Figure Legends from Hsp90 Inhibitor Ganetespib Sensitizes Non–Small Cell Lung Cancer to Radiation but Has Variable Effects with Chemoradiation
Authors: Wang Yifan , Liu Hui , Diao Lixia , Potter Adam , Zhang Jianhu , Qiao Yawei , Wang Jing , Proia David A. , Tailor Ramesh , Komaki Ritsuko , Lin Steven H.
Published: April 2023

Figure Legends for supplemental figure 1-5
Supplementary material from The Spectrum and Clinical Impact of Epigenetic Modifier Mutations in Myeloma
Authors: Pawlyn Charlotte , Kaiser Martin F. , Heuck Christoph , Melchor Lorenzo , Wardell Christopher P. , Murison Alex , Chavan Shweta S. , Johnson David C. , Begum Dil B. , Dahir Nasrin M. , Proszek Paula Z. , Cairns David A. , Boyle Eileen M. , Jones John R. , Cook Gordon , Drayson Mark T. , Owen Roger G. , Gregory Walter M. , Jackson Graham H. , Barlogie Bart , Davies Faith E. , Walker Brian A. , Morgan Gareth J.
Published: April 2023

Supplementary Tables: Supplementary table 1: Demographics of the 463 patients included in the Myeloma XI analysis Supplementary table 2: List of epigenetic modifier genes used to interrogate the list of mutations in the Myeloma XI dataset Supplementary table 3: Demographics of the 156 patients included in the UAMS dataset Supplementary table 4: List of epigenetic modifier genes sequenced in UAMS dataset Supplementary table 5: SIFT analysis of Histone 1 family gene mutations Supplementary table 6: Multivariate cox-regression model for overall survival in Myeloma XI patients Supplementary table 7: Percentage of patients with mutations in genes encoding epigenetic modifiers sequenced in both the MYXI and UAMS datasets (as shown in Supplementary table 4) - Supplementary Figures: Supplementary Figure 1: Epigenetic genes mutated in {greater than or equal to}5/463 patients (>1%) in Myeloma XI dataset - location of mutation with respect to protein functional domains Supplementary Figure 2: Translocation subgroup distribution by presence or absence of epigenetic modifier mutation in the Myeloma XI dataset Supplementary Figure 3: Survival curves for Histone 1 mutations in Myeloma XI dataset Supplementary Figure 4: A comparison of the variant allele frequency between the MyXI and UAMS mutations Supplementary Figure 5: The distribution of mutations in epigenetic modifiers in previously treated patients by GEP70 risk score Supplementary Figure 6: A comparison of the UAMS molecular subgroup distribution by presence of epigenetic modifier mutations in previously treated patients
Table S3 from SPARC Expression Did Not Predict Efficacy of nab-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial
Authors: Hidalgo Manuel , Plaza Carlos , Musteanu Monica , Illei Peter , Brachmann Carrie B. , Heise Carla , Pierce Daniel , Lopez-Casas Pedro P. , Menendez Camino , Tabernero Josep , Romano Alfredo , Wei Xinyu , Lopez-Rios Fernando , Von Hoff Daniel D.
Published: April 2023

Table S3. Baseline Characteristics in the Plasma SPARC-Evaluable Population
Supplementary figure legend from Maternal Embryonic Leucine Zipper Kinase (MELK) as a Novel Mediator and Biomarker of Radioresistance in Human Breast Cancer
Authors: Speers Corey , Zhao Shuang G. , Kothari Vishal , Santola Alyssa , Liu Meilan , Wilder-Romans Kari , Evans Joseph , Batra Nidhi , Bartelink Harry , Hayes Daniel F. , Lawrence Theodore S. , Brown Powel H. , Pierce Lori J. , Feng Felix Y.
Published: April 2023

Describes the supplementary figures 1-10
supplementary figure legends from SIRT1-Activating Compounds (STAC) Negatively Regulate Pancreatic Cancer Cell Growth and Viability Through a SIRT1 Lysosomal-Dependent Pathway
Authors: Chini Claudia C.S. , Espindola-Netto Jair M. , Mondal Gourish , Guerrico Anatilde M. Gonzalez , Nin Veronica , Escande Carlos , Sola-Penna Mauro , Zhang Jin-San , Billadeau Daniel D. , Chini Eduardo N.
Published: April 2023

supplementary figure legends S1-S15
Supplementary data from Dual Disruption of DNA Repair and Telomere Maintenance for the Treatment of Head and Neck Cancer
Authors: Lajud Shayanne A. , Nagda Danish A. , Yamashita Taku , Zheng Jun , Tanaka Nobuaki , Abuzeid Waleed M. , Civantos Alyssa , Bezpalko Orysia , O'Malley Bert W. , Li Daqing
Published: April 2023

Supplementary data. - Suppl. Figure 1 - Schematic of Ad-Nbs1 vector - Suppl. Figure 2 - BRCA status and Telomere maintenance status - Suppl. Figure 3 - Telomere instability - Suppl. Figure 4 - In vivo GFP expression - Suppl. Figure 5 - In vivo apoptosis representative pictures
Supplementary Table 3 from HMGB1 and Its Hyperacetylated Isoform are Sensitive and Specific Serum Biomarkers to Detect Asbestos Exposure and to Identify Mesothelioma Patients
Authors: Napolitano Andrea , Antoine Daniel J. , Pellegrini Laura , Baumann Francine , Pagano Ian , Pastorino Sandra , Goparaju Chandra M. , Prokrym Kirill , Canino Claudia , Pass Harvey I. , Carbone Michele , Yang Haining
Published: April 2023

Levels of other biomarkers in studied cohorts
Supplementary Table S3 from Myc-Driven Glycolysis Is a Therapeutic Target in Glioblastoma
Authors: Tateishi Kensuke , Iafrate A. John , Ho Quan , Curry William T. , Batchelor Tracy T. , Flaherty Keith T. , Onozato Maristela L. , Lelic Nina , Sundaram Sudhandra , Cahill Daniel P. , Chi Andrew S. , Wakimoto Hiroaki
Published: April 2023

Supplemental Table S3 Quantitative Estimation of Target Metabolitesï¼^Total Amount)
Supplementary Figure 1 from Circulating Cell-Free Tumor DNA Analysis of 50 Genes by Next-Generation Sequencing in the Prospective MOSCATO Trial
Authors: Jovelet Cécile , Ileana Ecaterina , Le Deley Marie-Cécile , Motté Nelly , Rosellini Silvia , Romero Alfredo , Lefebvre Celine , Pedrero Marion , Pata-Merci Noémie , Droin Nathalie , Deloger Marc , Massard Christophe , Hollebecque Antoine , Ferté Charles , Boichard Amélie , Postel-Vinay Sophie , Ngo-Camus Maud , De Baere Thierry , Vielh Philippe , Scoazec Jean-Yves , Vassal Gilles , Eggermont Alexander , André Fabrice , Soria Jean-Charles , Lacroix Ludovic
Published: April 2023

Sensitivity Prediction Score ROC Curve of the logistic regression model.
Supplementary Tables 1-7 from Genomic Classification of Serous Ovarian Cancer with Adjacent Borderline Differentiates RAS Pathway and TP53-Mutant Tumors and Identifies NRAS as an Oncogenic Driver
Authors: Emmanuel Catherine , Chiew Yoke-Eng , George Joshy , Etemadmoghadam Dariush , Anglesio Michael S. , Sharma Raghwa , Russell Peter , Kennedy Catherine , Fereday Sian , Hung Jillian , Galletta Laura , Hogg Russell , Wain Gerard V. , Brand Alison , Balleine Rosemary , MacConaill Laura , Palescandolo Emanuele , Hunter Sally M. , Campbell Ian , Dobrovic Alexander , Wong Stephen Q. , Do Hongdo , Clarke Christine L. , Harnett Paul R. , Bowtell David D.L. , deFazio Anna
Published: April 2023

Supplementary Tables 1-7. Supplementary Table 1. SBT-EOC cases used for molecular analyses Supplementary Table 2. Mutations Screened on the Sequenom/OncoMap3 Platform Supplementary Table 3. Primer sequences for the indicated exons of TP53, ERBB2 and NRAS Supplementary Table 4. Clinico-pathologic characteristics of the subset of SBT-EOC used for molecular analysis compared to the entire SBT-EOC cohort Supplementary Table 5A. Somatic mutations found in borderline and invasive ovarian tumors Supplementary Table 5B. Genes in which somatic mutations were found according to grade and co-existing serous borderline regions Supplementary Table 6. Genes differentially expressed between paired borderline and invasive regions of SBTEOC (p<0.01, not corrected for multiple comparison). Supplementary Table 7. Clinico-pathological characteristics of SBTEOC cases used for progesterone receptor (PGR) immunostaining
Supplementary Methods, Figures 1-5 from Genomic Classification of Serous Ovarian Cancer with Adjacent Borderline Differentiates RAS Pathway and TP53-Mutant Tumors and Identifies NRAS as an Oncogenic Driver
Authors: Emmanuel Catherine , Chiew Yoke-Eng , George Joshy , Etemadmoghadam Dariush , Anglesio Michael S. , Sharma Raghwa , Russell Peter , Kennedy Catherine , Fereday Sian , Hung Jillian , Galletta Laura , Hogg Russell , Wain Gerard V. , Brand Alison , Balleine Rosemary , MacConaill Laura , Palescandolo Emanuele , Hunter Sally M. , Campbell Ian , Dobrovic Alexander , Wong Stephen Q. , Do Hongdo , Clarke Christine L. , Harnett Paul R. , Bowtell David D.L. , deFazio Anna
Published: April 2023

Supplementary Methods, Figures 1-5. Supplementary Figure 1. Outline of cohort selection. Supplementary Figure 2. Example of whole-genome single-nucleotide polymorphism (SNP)array profile and genome alteration print (GAP). Supplementary Figure 3. Pre-treatment serum CA125 levels. Supplementary Figure 4. Progression-free and overall survival in patients with SBT-EOC and EOC without adjacent SBT. Supplementary Figure 5. Progression-free and overall survival of patients with Grade 3 SBTEOC and Grade 3 EOC without adjacent SBT
Supplementary Figures S1-S3, Materials and Methods from Safety and Efficacy of VCN-01, an Oncolytic Adenovirus Combining Fiber HSG-Binding Domain Replacement with RGD and Hyaluronidase Expression
Authors: Rodríguez-García Alba , Giménez-Alejandre Marta , Rojas Juan J. , Moreno Rafael , Bazan-Peregrino Miriam , Cascalló Manel , Alemany Ramon
Published: April 2023

Supplementary Figures S1-S3, Materials and Methods. Supplementary Figure S1. Pharmacokinetic profile of VCN-01 in immunocompetent mice. Supplementary Figure S2. Toxicity after systemic administration of VCN-01 in immunocompetent Syrian hamster. Supplementary Figure S3. Kaplan-Meier survival curves after intratumoral administration of VCN-01. Supplementary Material and Methods: Fluorescence In Situ Hybridization (FISH)